DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
Loading...
  • Stocks
  • /
  • Insurance
Updated 1d ago
NXG logo

NexgenRx Inc.TSXV:NXG Stock Report

Market Cap CA$43.4m
Updated 1d ago
Share Price
n/a
1Y70.0%
7D9.7%
1D11.5%
Portfolio Value
​
View

NexgenRx Inc.

TSXV:NXG Stock Report

Market Cap: CA$43.4m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

NexgenRx (NXG) Stock Overview

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. More details

NXG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends3/6

Rewards

Earnings grew by 194.2% over the past year

Risk Analysis

Earnings have declined by 26.7% per year over past 5 years

Unstable dividend track record

Does not have a meaningful market cap (CA$43M)

Volatile share price over the past 3 months compared to the Canadian market


NXG Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW435,612 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
435,612 investors already sharing narratives
CA$
Current Price
CA$0.6819.0% undervalued intrinsic discount
%/yr
Decrease
Increase
PastFuture-1m33m2016201920222025202620282031Revenue CA$32.7mEarnings CA$4.0m
Advanced
View all narratives

NexgenRx Inc. Competitors

Taiming Assurance BrokerLtd

Symbol: TPEX:5878
Market cap: NT$954.7m

IRRC

Symbol: TSE:7325
Market cap: JP¥5.7b

TQR

Symbol: SET:TQR
Market cap: ฿1.4b

Transilvania Broker de Asigurare

Symbol: BVB:TBK
Market cap: RON 83.0m

Price History & Performance

Summary of share price highs, lows and changes for NexgenRx
Historical stock prices
Current Share PriceCA$0.68
52 Week HighCA$0.75
52 Week LowCA$0.29
Beta0.49
1 Month Change13.33%
3 Month Change51.11%
1 Year Change70.00%
3 Year Change151.85%
5 Year Change100.00%
Change since IPO94.29%

Recent News & Updates

Analysis Article • May 23

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Recent updates

Analysis Article • May 23

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Jul 01

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 29% But Growth Is Lacking

The NexgenRx Inc. ( CVE:NXG ) share price has done very well over the last month, posting an excellent gain of 29%. The...
Analysis Article • Apr 07

Pinning Down NexgenRx Inc.'s (CVE:NXG) P/S Is Difficult Right Now

It's not a stretch to say that NexgenRx Inc.'s ( CVE:NXG ) price-to-sales (or "P/S") ratio of 1.1x right now seems...
Analysis Article • May 21

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

NexgenRx Inc. ( CVE:NXG ) shares have had a really impressive month, gaining 45% after a shaky period beforehand. While...
Analysis Article • May 10

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Key Insights NexgenRx's Annual General Meeting to take place on 16th of May Total pay for CEO Ron Loucks includes...
Analysis Article • Mar 14

NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

With a median price-to-sales (or "P/S") ratio of close to 1.2x in the Insurance industry in Canada, you could be...
Analysis Article • Mar 07

Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Oct 18

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Nov 30

Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Aug 24

What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

NexgenRx Inc. ( CVE:NXG ) shareholders would be excited to see that the share price has had a great month, posting a...
Analysis Article • Jun 03

Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

Shareholders will probably not be disappointed by the robust results at NexgenRx Inc. ( CVE:NXG ) recently and they...
Analysis Article • Feb 19

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

NexgenRx (CVE:NXG) has had a great run on the share market with its stock up by a significant 43% over the last three...
Analysis Article • Dec 28

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Ron Loucks became the CEO of NexgenRx Inc. ( CVE:NXG ) in 2003, and we think it's a good time to look at the...

Shareholder Returns

NXGCA InsuranceCA Market
7D9.7%-1.7%-0.1%
1Y70.0%27.9%23.9%

Return vs Industry: NXG exceeded the Canadian Insurance industry which returned 29.3% over the past year.

Return vs Market: NXG exceeded the Canadian Market which returned 24.6% over the past year.

Price Volatility

Is NXG's price volatile compared to industry and market?
NXG volatility
NXG Average Weekly Movement13.2%
Insurance Industry Average Movement2.9%
Market Average Movement9.4%
10% most volatile stocks in CA Market16.3%
10% least volatile stocks in CA Market3.7%

Stable Share Price: NXG's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: NXG's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
2003n/aRon Louckswww.nexgenrx.com

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides proprietary computer software, and ancillary services.

NexgenRx Inc. Fundamentals Summary

How do NexgenRx's earnings and revenue compare to its market cap?
NXG fundamental statistics
Market capCA$43.38m
Earnings (TTM)CA$2.37m
Revenue (TTM)CA$19.34m
20.4x
P/E Ratio
2.5x
P/S Ratio

Is NXG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NXG income statement (TTM)
RevenueCA$19.34m
Cost of RevenueCA$2.92m
Gross ProfitCA$16.42m
Other ExpensesCA$14.05m
EarningsCA$2.37m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)0.033
Gross Margin84.89%
Net Profit Margin12.23%
Debt/Equity Ratio0%

How did NXG perform over the long term?

See historical performance and comparison

Dividends

2.2%
Current Dividend Yield
47%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 00:34
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NexgenRx Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide